Jaime Eaglin Moore, MD; Andrew Heller, MD
A 60-year-old man presented to our otolaryngology clinic with a 2-week history of dysphonia. One month earlier at another surgical service, the patient had undergone a percutaneous tracheotomy in the medical intensive care unit following a cardiac event. He was weaned from ventilator support several days later, and he subsequently had his tracheotomy tube downsized.
On initial examination, the patient exhibited a breathy, severely dysphonic voice. He was unable to tolerate capping trials. Flexible laryngoscopy revealed a posteriorly displaced epiglottis with submucosal pre-epiglottic fullness. The view of the true vocal folds was limited, but their movement was noted to be symmetric and hypomobile. Laryngeal landmarks could not be palpated. Computed tomography (CT) showed the tracheotomy tube entering the larynx through the superior portion of the anterior thyroid cartilage with significant posterosuperior displacement of the cartilage (figures 1 and 2).
The patient was taken to the operating room for direct laryngoscopy, a revision of his tracheotomy tube site, and an attempted repair of the fractured thyroid cartilage. Efforts to mobilize the cartilage without causing further fracture and distortion of the architecture were unsuccessful. Further surgical intervention-including refracturing and rigid fixation of the thyroid cartilage-was discussed with the patient, but he declined further intervention because his medical comorbidities placed him at significant operative risk and because he was satisfied with his current voice. The patient is currently tracheotomy-tube-dependent.
For percutaneous tracheotomy tube placement, research has shown a significantly higher risk of complications in patients whose body mass index (BMI) is 30 
LARYNGOSCOPIC CLINIC
The potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of safe and effective noncorticosteroid treatment alternatives. To minimize the systemic effects of intranasal corticosteroids, each patient should be titrated to the lowest dose that effectively controls his/her symptoms.
The potential for ZETONNA Nasal Aerosol to cause growth suppression in susceptible patients or when given at higher than recommended dosages cannot be ruled out.
Geriatric Use
Clinical trials of ZETONNA Nasal Aerosol did not include sufficient numbers of patients age 65 and over to determine whether they responded differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
OVERDOSAGE
Chronic overdosage may result in signs or symptoms of hypercorticism [see Warnings and Precautions (5.5)]. There are no data on the effects of acute or chronic overdosage with ZETONNA Nasal Aerosol. or greater. 1 Our patient's BMI was 50.8. These patients have a higher likelihood of a distorted anatomy, which can make tube placement difficult. The use of the bronchoscope for visualization has been shown to decrease the incidence of major complications, which are usually related to incorrect placement. 1 A bronchoscope was used during our patient's initial procedure. A study looking at cartilage injuries associated with percutaneous tracheotomy tube placement found an incorrect placement in 3 of 6 cadavers. 2 The tube had been placed either higher than intended, lower than intended, or off midline. Five of the 6 cadavers had a grade 4 cartilage injury; grade 4, which was the highest injury grade in that study, was defined as a fracture with multiple comminutions. One of the cadavers exhibited injury to the cricoid cartilage.
STORAGE
To the best of our knowledge, ours is the first reported case of an in vivo injury to the thyroid cartilage sustained during percutaneous tracheotomy tube placement.
